Imprifab
ActiveSummary
Imprifab has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€9,130) and a net result of €1,802. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 15% of 147 sector peers (NACE 20, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Imprifab
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, bij enkel besluit bestuursorgaan administratieve zetels,agentschappen,werkhuizen,stapelplaatsen en bijkantoren vestigen in…” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Bestuursorgaan, 11” (deed in Dutch)“13, algemene vergadering” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Op naam, TITEL III. EFFECTEN” (deed in Dutch)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “10, zelfde formaliteiten indien geen aandeelhouder van rechtswege” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Friday of June at 14:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- One provision in the deed
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Algemene vergadering kan een of meerdere vereffenaars aanduiden bevoegdheden omlijnen vergoeding bepalen, bestuurder(s) in functie krachtens…” (deed in Dutch)